Skip to main content

Table 6 Health care resource use associated with procedures

From: Health care resource use among patients with advanced non-small cell lung cancer: the PIvOTAL retrospective observational study

 

Italy

Spain

Germany

Australia

Japan

Korea

Taiwan

Brazil

1LT

2LT

1LT

2LT

1LT

2LT

1LT

2LT

1LT

2LT

1LT

2LT

1LT

2LT

1LT

2LT

N = 174

N = 101

N = 202

N = 96

N = 139

N = 64

N = 208

N = 128

N = 175

N = 105

N = 150

N = 96

N = 217

N = 155

N = 175

N = 91

No. imaging tests, n

155

85

186

72

133

53

191

115

160

97

142

91

192

117

149

72

 Mean (SD)

3.4 (2.6)

3.0 (3.1)

4.6 (3.4)

3.9 (3.3)

7.0 (4.9)

5.3 (3.4)

5.4 (5.0)

4.7 (4.3)

16.7 (12.7)

10.2 (7.8)

9.3 (8.7)

10.0 (8.9)

11.5 (13.4)

10.6 (14.8)

3.6 (3.7)

3.0 (2.4)

 Median (range)

3 (1–13)

2 (1–17)

4 (1–23)

3 (1–21)

6 (1–31)

5 (1–16)

4 (1–33)

3 (1–23)

14 (1–68)

8 (1–39)

7 (1–75)

8 (1–48)

8 (1–86)

5 (1–86)

3 (1–31)

2 (1–11)

Imaging test type, n (%)a

 Radiograph

42 (27)

16 (19)

77 (41)

25 (35)

93 (70)

30 (57)

112 (59)

55 (48)

147 (92)

87 (90)

99 (70)

68 (75)

123 (64)

87 (74)

16 (11)

7 (10)

 PET scan

45 (29)

12 (14)

39 (21)

5 (7)

41 (31)

5 (9)

56 (29)

7 (6)

14 (9)

4 (4)

99 (70)

22 (24)

42 (22)

1 (1)

43 (29)

6 (8)

 CT scan

146 (94)

78 (92)

173 (93)

65 (90)

127 (96)

48 (91)

170 (89)

109 (95)

145 (91)

88 (91)

131 (92)

90 (99)

180 (94)

86 (74)

136 (91)

69 (96)

 MRI

28 (18)

10 (12)

70 (38)

21 (29)

56 (42)

12 (23)

32 (17)

20 (17)

107 (67)

58 (60)

103 (73)

33 (36)

72 (38)

32 (27)

52 (35)

15 (21)

 Ultrasound

8 (5)

6 (7)

18 (10)

2 (3)

19 (14)

2 (4)

46 (24)

17 (15)

19 (12)

2 (2)

25 (18)

5 (6)

39 (20)

19 (16)

8 (5)

5 (7)

 Other

16 (10)

4 (5)

32 (17)

10 (14)

61 (46)

9 (17)

38 (20)

15 (13)

92 (58)

31 (32)

53 (37)

29 (32)

102 (53)

26 (22)

48 (32)

11 (15)

No. biopsy-related procedure

129

1

147

3

124

3

146

1

147

0

129

3

168

2

113

1

 Mean (SD)

1.0 (0.2)

1 (n/a)

1.1 (0.3)

1.0 (0)

1.2 (0.4)

1.0 (0)

1.1 (0.3)

1.0 (n/a)

1.1 (0.4)

n/a

1.2 (0.4)

1.3 (0.6)

1.1 (0.2)

1.0 (0)

1.0 (0.2)

n/a

 Median (range)

1 (1–2)

1

1 (1–3)

1 (1–1)

1 (1–4)

1 (1–1)

1 (1–3)

1 (1–1)

1 (1–5)

n/a

1 (1–2)

1 (1–2)

1 (1–2)

1 (1–1)

1 (1–2)

1 (1–1)

No. biomarker tests

67

6

120

10

67

3

89

16

84

2

102

6

150

3

45

11

 Mean (SD)

1.2 (0.4)

1 (0)

1.5 (0.9)

1.0 (0)

2.4 (1.4)

1.7 (1.2)

1.5 (0.8)

1.7 (1.1)

1.1 (0.4)

1.0 (0)

2.2 (0.9)

1.7 (1.2)

1.0 (0)

1.0 (0)

1.1 (0.3)

1.2 (0.4)

 Median (range)

1 (1–2)

1 (1–1)

1 (1–6)

1 (1–1)

2 (1–8)

1 (1–3)

1 (1–3)

1 (1–5)

1 (1–2)

1 (1–1)

2 (1–4)

1 (1–4)

1 (1–1)

1 (1–1)

1 (1–2)

1 (1–2)

Test type, number

 ALK

17

4

30

1

34

2

16

8

14

1

48

2

0

0

7

4

 EGFR

64

2

110

8

62

1

85

10

81

1

96

5

150

3

42

8

 Other

2

0

18

1

47

2

29

7

0

0

80

2

0

0

0

1

  1. aIn Germany, the imaging test type was unknown or missing for two imaging tests during first-line and one imaging test during second-line therapy
  2. 1LT first-line therapy, 2LT second-line therapy, ALK anaplastic lymphoma kinase, CT computed tomography, EGFR epidermal growth factor receptor, LOS length of stay, MRI magnetic resonance imaging, n/a not applicable, No. number of, OP outpatient, PET positron emission tomography
Back to article page

BMC Health Services Research

ISSN: 1472-6963

Contact us